Two Research Teams Converge on Single-Dose Malaria Treatments as Resistance Grows

Researchers at the University of Dundee have identified a novel compound, cabamiquine, that demonstrates antimalarial activity in a single dose when paired with the existing drug pyronaridine. Separately, the German Center for Infection Research (DZIF) has developed SPAP, a four-drug combination designed for single-dose use, now advancing to a pan-African clinical trial. The parallel progress marks a convergent shift in malaria drug development toward regimens that patients can complete in one sitting.

The scale of the problem underscores the urgency. Global malaria data for 2024 show an estimated 282 million cases and 610,000 deaths. Those numbers are escalating partly because resistance to current therapies is increasing, complicating the multi-dose regimens that have been the standard of care. When treatment requires several days of pills, adherence falters — especially in low-resource settings where access to healthcare is intermittent and patients may stop taking medication once symptoms subside. Incomplete courses give parasites the opportunity to survive and develop resistance, creating a cycle that erodes the effectiveness of existing drugs.

Cabamiquine emerged from Dundee's drug discovery unit as a "novel drug-like molecule" with the potential to streamline dosing for both prevention and treatment. Early-stage trial results showed that a single dose combined with pyronaridine cleared parasites effectively. The compound represents a new chemical class, which matters because cross-resistance with current frontline therapies is less likely. Pyronaridine itself is already used in combination with artesunate, but pairing it with a new partner could extend its useful life.

In Germany, DZIF researchers took a different approach. Rather than a single new molecule, they assembled SPAP from four existing drugs with complementary mechanisms. The combination is designed to hit the parasite at multiple stages simultaneously, reducing the probability that resistance will emerge. DZIF is now preparing SPAP for large-scale clinical testing across Africa, the continent that bears the overwhelming share of malaria cases and deaths. A pan-African trial will test efficacy and safety across diverse transmission settings and patient populations.

Both strategies address the same core failure of current treatment: the gap between what a regimen requires and what patients can realistically complete. A single dose eliminates the adherence cliff. It also simplifies supply chains — one blister pack instead of several — and reduces the burden on community health workers who currently must observe or track multi-day courses. For prevention, a single-dose option could transform seasonal malaria chemoprevention campaigns that currently require monthly visits over four months.

The convergence of two independent programs on the same goal suggests the field has reached a consensus on the target product profile. Regulatory pathways for single-dose combinations are being defined. Manufacturing costs will determine whether these regimens reach the populations that need them most. Both cabamiquine and SPAP must still demonstrate safety and tolerability in larger human trials. The DZIF pan-African trial will provide the first large-scale efficacy data for a four-drug single-dose combination. Dundee's cabamiquine program will need to move through later-phase trials, likely in combination with pyronaridine or another partner.

Open questions remain. The full safety profiles of both regimens in children, pregnant women, and patients with comorbidities are not yet known. The timeline for regulatory approval depends on trial outcomes that have not yet been generated. Manufacturing at scale for African markets will require technology transfer agreements and financing mechanisms that do not yet exist. Distribution logistics — cold chain requirements, shelf life, packaging — will shape real-world access as much as clinical efficacy.

What is clear is that the pipeline has shifted. For years, the emphasis was on improving existing multi-dose combinations. Now, two well-resourced research centers have independently concluded that the next step change in malaria treatment must be a single pill. If either succeeds, it would represent the most significant simplification of malaria therapy since artemisinin-based combinations replaced monotherapies two decades ago. The parasite will not wait. Resistance continues to spread. The race between drug development and parasite evolution has entered a new phase.